Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win

Novo Nordisk's oral Wegovy has captured approximately 89% of oral weight-loss medication prescriptions in the U.S., regaining market share in the GLP-1 obesity treatment space. The pill formulation marks a significant milestone for the Danish drugmaker as it competes head-to-head with Eli Lilly in the rapidly expanding anti-obesity market.

Despite Novo's oral Wegovy momentum, Eli Lilly's competing asset Foundayo offers distinct advantages. Foundayo requires fewer food restrictions than oral Wegovy, potentially improving patient adherence. More importantly, Lilly is pursuing label expansions for Foundayo across multiple indications beyond weight loss, which could broaden the drug's addressable market and revenue potential.

Both pharmaceutical giants maintain strong pipeline positions in GLP-1 therapies, a category that continues to see robust demand as obesity treatment becomes a larger focus for healthcare spending. The oral formulation race represents a critical battleground, as pill-based options eliminate the injection barrier that has limited patient adoption of earlier GLP-1 drugs.